Claims

1. A vaccine for the therapeutic or prophylactic immunisation against Venezuelan Equine Encephalitis (VEE) virus, said vaccine comprising a vector which includes a sequence which encodes an attenuated form of said virus which is capable of producing a protective immune response, wherein the said sequence is such that the amino acid at position 7 in the E2 protein of VEE is lysine.

10

- 2. A vaccine according to claim 1 wherein the attenuated form of said virus comprises a derivative of the TC-83 construct.
- 3. A vaccine according to claim 2 wherein the vector comprises a virus vector.
 - 4. A vaccine according to claim 3 wherein the virus is selected from an attenuated virus
- 20 5. A vaccine according to claim 3 or claim 4 wherein the virus is selected from vaccinia, adenovirus, HSV, BCG or BCC.
 - 6. A vaccine according to claim 5 which comprises an attenuated vaccinia virus.

25

30

- 7. A vaccine according to claim 6 wherein expression of the said attenuated VEE virus is under the control of a synthetic 7.5K vaccinia promoter which has been subject to mutation which increases the level of VEE virus protein production as compared to the wild-type 7.5K promoter.
- 8. A vaccine according to claim 7 wherein the said 7.5K promoter comprises a sequence selected from

TAAAAATTGAAAATACATTCTAATTTATTGCAC (SEQ ID No 2)

35 or

40

TAAAAATTGAAAATATATTCTAATTTATTGCAC (SEQ ID No 3).

9. A vaccine according to any one of the preceding claims which comprises a vector which includes a nucleotide sequence which encodes a further immunogenic peptide, and is able to express said sequence when administered to a mammal.

5

10

30

35

- 10. A vaccine according to any one of the preceding claims which further comprises a cytokine or an active fragement or variant thereof, or a vector which comprises a nucleotide sequence which encodes a cytokine or an active fragment or variant thereof.
- 11. A vaccine according to claim 10 which comprises a vector which comprises a nucleotide sequence which encodes a cytokine or an active fragment or variant thereof.
- 12. A vaccine according to claim 10 or claim 11 wherein the cytokine is an interleukin.
- 13. A vaccine according to claim 10 wherein the interleukin is selected from human IL-2 or human IL-6.
- 14. A vaccine for the therapeutic or prophylactic immunisation against Venezuelan Equine Encephalitis (VEE) virus, said vaccine comprising a vaccinia virus vector which encodes an attenuated form of the VEE virus or a variant or fragment thereof which is capable of producing a protective immune response against VEE virus, expression of the said attenuated VEE virus being under the control of a synthetic 7.5K vaccinia promoter which has been subject to mutation which increases the level of VEE virus protein production as compared to the wild-type 7.5K promoter
 - 15. A pharmaceutical composition comprising a vaccine as defined in any one of the preceding claims and a pharmaceutically acceptable carrier or excipient.
 - 16. A method for producing a protective immune response against VEE virus in a mammal, which method comprises administering to said mammal, a vaccine according to any one of claims 1 to 14.
 - 17. A method according to claim 16 wherein the mammal is either a human or a horse.
- 18. A multivalent vaccine comprising a vaccine according to 40 any one of claims 1 to 14 and a further vaccine.